Form 4: Lantheus Holdings Executive Provost Receives Stock Options and Restricted Stock Units

Jean-Claude Provost, Chief Medical Officer of Lantheus Holdings, reports acquisition of stock options and restricted stock units.

Summary

• Jean-Claude Provost, Chief Medical Officer of Lantheus Holdings, Inc., filed a Form 4 on March 5, 2024, reporting transactions that occurred on March 1, 2024.
• Provost acquired 18,564 shares of Common Stock indirectly through Theranostics Consulting SAS, at a price of $0.00.
• Following the transaction, Provost beneficially owns 39,387 shares of Common Stock indirectly.
• Provost also acquired 10,998 stock options (right to buy) indirectly through Theranostics Consulting SAS, with an exercise price of $64.64.
• These options vest in three equal annual installments beginning on March 1, 2025, and expire on March 1, 2034.
• Provost also received 6,188 restricted stock units that vest in equal installments over a three-year period and 12,376 Total Shareholder Return performance-based restricted stock units ('PSUs') that cliff vest following a three-year performance period.
• The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as they align management's interests with shareholders.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule of the options and restricted stock units encourages long-term commitment from the executive.

Risks

• The value of the stock options is dependent on the future performance of Lantheus Holdings' stock price.
• The ultimate value of the PSUs is dependent on the actual performance achieved at the end of the performance period, which can range from 0% to 200% of the target.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options and restricted stock units.

Industry Context

This type of equity compensation is common in the pharmaceutical and biotechnology industries to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Equity compensation packages for Chief Medical Officers in similar-sized pharmaceutical companies typically include a mix of stock options, restricted stock units, and performance-based awards.
• The vesting schedules and performance metrics are often tailored to the specific goals and priorities of the company.
• Comparable companies such as Myriad Genetics, Exact Sciences, and NeoGenomics also utilize similar equity compensation strategies.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to improve company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates